D. Boral Capital Reaffirms "Buy" Rating for Invivyd (NASDAQ:IVVD)

Invivyd (NASDAQ:IVVD - Get Free Report)'s stock had its "buy" rating reaffirmed by equities research analysts at D. Boral Capital in a research note issued on Thursday,Benzinga reports. They presently have a $9.00 price target on the stock.

Separately, HC Wainwright lowered their price objective on Invivyd from $10.00 to $5.00 and set a "buy" rating on the stock in a research report on Wednesday, May 28th.

Invivyd Stock Performance

NASDAQ IVVD opened at $0.70 on Thursday. The stock has a 50-day moving average of $0.75 and a 200 day moving average of $0.76. Invivyd has a one year low of $0.35 and a one year high of $2.74. The company has a market capitalization of $84.49 million, a price-to-earnings ratio of -0.59 and a beta of 0.63.

Invivyd (NASDAQ:IVVD - Get Free Report) last released its quarterly earnings results on Thursday, May 15th. The company reported ($0.14) earnings per share for the quarter, missing the consensus estimate of ($0.04) by ($0.10). The firm had revenue of $11.30 million for the quarter, compared to the consensus estimate of $34.45 million. Invivyd had a negative net margin of 389.01% and a negative return on equity of 165.24%. On average, equities analysts predict that Invivyd will post -1.64 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the business. JPMorgan Chase & Co. grew its position in shares of Invivyd by 644.1% during the fourth quarter. JPMorgan Chase & Co. now owns 256,900 shares of the company's stock worth $114,000 after buying an additional 222,375 shares in the last quarter. Two Sigma Advisers LP lifted its stake in shares of Invivyd by 1,276.5% in the fourth quarter. Two Sigma Advisers LP now owns 304,200 shares of the company's stock valued at $135,000 after purchasing an additional 282,100 shares during the period. Mithril II GP LP acquired a new position in Invivyd during the fourth quarter worth $4,981,000. Deutsche Bank AG increased its holdings in Invivyd by 35.2% during the 4th quarter. Deutsche Bank AG now owns 874,406 shares of the company's stock valued at $385,000 after acquiring an additional 227,463 shares in the last quarter. Finally, Two Sigma Investments LP lifted its holdings in Invivyd by 125.3% in the 4th quarter. Two Sigma Investments LP now owns 367,100 shares of the company's stock valued at $163,000 after purchasing an additional 204,188 shares in the last quarter. 70.36% of the stock is owned by institutional investors and hedge funds.

About Invivyd

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.